Logo

Amgen's Aimovig (erenumab-aooe) Receives FDA's Approval for Prevention of Migraine in Adults

Share this

Amgen's Aimovig (erenumab-aooe) Receives FDA's Approval for Prevention of Migraine in Adults

Shots:

  • The approval is based on P-IIIb LIBERTY (NCT03096834) study results assessing Aimovig (140mg) vs PBO for duration of 12 weeks
  • The study resulted in 50% reduction of monthly migraine days sustained up to 15 months with the use of acute migraine drugs
  • Aimovig (erenumab-aooe) is a novel drug used for targeting Calcitonin Gene-Related Peptide Receptor (CGRP-R)- with its awaited EMA approval

Ref: Amgen | Image: Axios

 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions